Oncogenes and tumor suppressor genes in malignant mesothelioma

Robert A Kratzke, Adi F. Gazdar

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Conclusion: Mesothelioma is a cancer marked by a distinct pattern of mutations unlike most other solid tumors. Direct mutation of genes such as p53 or ras family members may be rare and distinctly different from the well-characterized spectrum of mutations seen in the more common epithelial malignancies such as lung or bladder cancer. This may be partially a result of the unique contributions of asbestos and SV40 infection as co-carcinogens in mesothelioma. Nonetheless, aberrations of the regulatory genes expressed at the 9p21 locus (p16 INK4a, p14 ARF) and chromosome 22 (NF2) are clearly among the highest frequencies observed in human cancers. In addition, recent investigations into epigenetic inactivation following SV40 infection may yield new gene targets such as RASSF1A that are inactivated by pathways that have not been sufficiently explored in the past. The presence of normal DNA within mesothelioma tumors is likely not to be equated with the presence of a normal protein phenotype in the future. This holds the promise of potentially reversible epigenetic or infectious molecular defects accounting for much of the transformed phenotype in mesothelioma, and the distinct possibility of novel therapeutic modalities that may reverse these acquired defects in gene expression patterns.

Original languageEnglish (US)
Title of host publicationMalignant Mesothelioma
Subtitle of host publicationAdvances in Pathogenesis, Diagnosis, and Translational Therapies
PublisherSpringer New York
Pages124-140
Number of pages17
ISBN (Print)0387229493, 9780387229492
DOIs
StatePublished - Dec 1 2005

Fingerprint

Tumor Suppressor Genes
Oncogenes
Mesothelioma
Neoplasms
Epigenomics
Mutation
Tumor Suppressor Protein p14ARF
Phenotype
Chromosomes, Human, Pair 22
Asbestos
Regulator Genes
Infection
Urinary Bladder Neoplasms
Carcinogens
Genes
Lung Neoplasms
Malignant Mesothelioma
Gene Expression
DNA
Proteins

Cite this

Kratzke, R. A., & Gazdar, A. F. (2005). Oncogenes and tumor suppressor genes in malignant mesothelioma. In Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies (pp. 124-140). Springer New York. https://doi.org/10.1007/0-387-28274-2_8

Oncogenes and tumor suppressor genes in malignant mesothelioma. / Kratzke, Robert A; Gazdar, Adi F.

Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies. Springer New York, 2005. p. 124-140.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kratzke, RA & Gazdar, AF 2005, Oncogenes and tumor suppressor genes in malignant mesothelioma. in Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies. Springer New York, pp. 124-140. https://doi.org/10.1007/0-387-28274-2_8
Kratzke RA, Gazdar AF. Oncogenes and tumor suppressor genes in malignant mesothelioma. In Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies. Springer New York. 2005. p. 124-140 https://doi.org/10.1007/0-387-28274-2_8
Kratzke, Robert A ; Gazdar, Adi F. / Oncogenes and tumor suppressor genes in malignant mesothelioma. Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies. Springer New York, 2005. pp. 124-140
@inbook{9a5ed1b6eb6c4f1abd160817e50d3ae5,
title = "Oncogenes and tumor suppressor genes in malignant mesothelioma",
abstract = "Conclusion: Mesothelioma is a cancer marked by a distinct pattern of mutations unlike most other solid tumors. Direct mutation of genes such as p53 or ras family members may be rare and distinctly different from the well-characterized spectrum of mutations seen in the more common epithelial malignancies such as lung or bladder cancer. This may be partially a result of the unique contributions of asbestos and SV40 infection as co-carcinogens in mesothelioma. Nonetheless, aberrations of the regulatory genes expressed at the 9p21 locus (p16 INK4a, p14 ARF) and chromosome 22 (NF2) are clearly among the highest frequencies observed in human cancers. In addition, recent investigations into epigenetic inactivation following SV40 infection may yield new gene targets such as RASSF1A that are inactivated by pathways that have not been sufficiently explored in the past. The presence of normal DNA within mesothelioma tumors is likely not to be equated with the presence of a normal protein phenotype in the future. This holds the promise of potentially reversible epigenetic or infectious molecular defects accounting for much of the transformed phenotype in mesothelioma, and the distinct possibility of novel therapeutic modalities that may reverse these acquired defects in gene expression patterns.",
author = "Kratzke, {Robert A} and Gazdar, {Adi F.}",
year = "2005",
month = "12",
day = "1",
doi = "10.1007/0-387-28274-2_8",
language = "English (US)",
isbn = "0387229493",
pages = "124--140",
booktitle = "Malignant Mesothelioma",
publisher = "Springer New York",

}

TY - CHAP

T1 - Oncogenes and tumor suppressor genes in malignant mesothelioma

AU - Kratzke, Robert A

AU - Gazdar, Adi F.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Conclusion: Mesothelioma is a cancer marked by a distinct pattern of mutations unlike most other solid tumors. Direct mutation of genes such as p53 or ras family members may be rare and distinctly different from the well-characterized spectrum of mutations seen in the more common epithelial malignancies such as lung or bladder cancer. This may be partially a result of the unique contributions of asbestos and SV40 infection as co-carcinogens in mesothelioma. Nonetheless, aberrations of the regulatory genes expressed at the 9p21 locus (p16 INK4a, p14 ARF) and chromosome 22 (NF2) are clearly among the highest frequencies observed in human cancers. In addition, recent investigations into epigenetic inactivation following SV40 infection may yield new gene targets such as RASSF1A that are inactivated by pathways that have not been sufficiently explored in the past. The presence of normal DNA within mesothelioma tumors is likely not to be equated with the presence of a normal protein phenotype in the future. This holds the promise of potentially reversible epigenetic or infectious molecular defects accounting for much of the transformed phenotype in mesothelioma, and the distinct possibility of novel therapeutic modalities that may reverse these acquired defects in gene expression patterns.

AB - Conclusion: Mesothelioma is a cancer marked by a distinct pattern of mutations unlike most other solid tumors. Direct mutation of genes such as p53 or ras family members may be rare and distinctly different from the well-characterized spectrum of mutations seen in the more common epithelial malignancies such as lung or bladder cancer. This may be partially a result of the unique contributions of asbestos and SV40 infection as co-carcinogens in mesothelioma. Nonetheless, aberrations of the regulatory genes expressed at the 9p21 locus (p16 INK4a, p14 ARF) and chromosome 22 (NF2) are clearly among the highest frequencies observed in human cancers. In addition, recent investigations into epigenetic inactivation following SV40 infection may yield new gene targets such as RASSF1A that are inactivated by pathways that have not been sufficiently explored in the past. The presence of normal DNA within mesothelioma tumors is likely not to be equated with the presence of a normal protein phenotype in the future. This holds the promise of potentially reversible epigenetic or infectious molecular defects accounting for much of the transformed phenotype in mesothelioma, and the distinct possibility of novel therapeutic modalities that may reverse these acquired defects in gene expression patterns.

UR - http://www.scopus.com/inward/record.url?scp=79959225066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959225066&partnerID=8YFLogxK

U2 - 10.1007/0-387-28274-2_8

DO - 10.1007/0-387-28274-2_8

M3 - Chapter

SN - 0387229493

SN - 9780387229492

SP - 124

EP - 140

BT - Malignant Mesothelioma

PB - Springer New York

ER -